BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36229592)

  • 41. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
    Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
    BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
    Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
    Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
    Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications.
    Vitale G; Carra S; Ferraù F; Guadagno E; Faggiano A; Colao A;
    Crit Rev Oncol Hematol; 2020 Feb; 146():102840. PubMed ID: 31918344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral cancer diagnostics based on infrared spectral markers and wax physisorption kinetics.
    Chiu LF; Huang PY; Chiang WF; Wong TY; Lin SH; Lee YC; Shieh DB
    Anal Bioanal Chem; 2013 Feb; 405(6):1995-2007. PubMed ID: 23318761
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [CT and MRI findings of primary hepatic neuroendocrine neoplasm].
    Li JK; Wang M; Yuan J; Song ZG
    Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):600-606. PubMed ID: 28835083
    [No Abstract]   [Full Text] [Related]  

  • 48. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
    Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging.
    Danti G; Flammia F; Matteuzzi B; Cozzi D; Berti V; Grazzini G; Pradella S; Recchia L; Brunese L; Miele V
    Radiol Med; 2021 Dec; 126(12):1497-1507. PubMed ID: 34427861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. G3 GEP NENs category: are basic and clinical investigations well integrated?
    Milione M; Fazio N
    Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
    Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
    Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
    Fang JM; Li J; Shi J
    World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent updates on grading and classification of neuroendocrine tumors.
    Kim JY; Hong SM; Ro JY
    Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
    Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis.
    Domori K; Nishikura K; Ajioka Y; Aoyagi Y
    Gastric Cancer; 2014 Apr; 17(2):263-72. PubMed ID: 23828549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
    Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
    Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.